Security Snapshot

Apyx Medical Corp - Common Stock, $0.001 par value per share (APYX) Institutional Ownership

CUSIP: 03837C106

13F Institutional Holders and Ownership History from Q4 2018 to Q3 2026

13F reference period

Q2 2026

Institutions Reporting

67

Shares (Excl. Options)

21.3MFull value: 21,301,578 · shares · 30 Jun 2026

Price

$4.49

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / Common Stock, $0.001 par value per share
Symbol
APYX on Nasdaq
All holders as of 30 Jun 2026
Q2 2026
Total 13F shares
21,301,578
Latest holder snapshot 5 signals
Total 13F value
$95,637,666
Portfolio coverage rank
0%
Share change
+491,802
Value change
+$2,357,661
Number of holders
67
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
42,231,815
SEC-reported price per share
$2.45
Insider filing price
$2.45
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • APYX - Apyx Medical Corp - Common Stock, $0.001 par value per share is tracked under CUSIP 03837C106.
  • 67 institutions reported positions in Q2 2026.
  • 3 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 67 to 67 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from
    $76.78MFull value: $76,784,547 · USD · 31 Mar 2026
    to
    $95.64MFull value: $95,637,666 · USD · 30 Jun 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 67 institutions filings for Q2 2026.

Open SEC evidence

Security key

03837C106

13F reference period

Q2 2026

13F holders

67

13D/G owners

3

CIK / CUSIP context first

Open Q2 2026 holders APYX full holder history Apyx Medical Corp SEC filings Apyx Medical Corp company facts Apyx Medical Corp insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
3
Security
APYX
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Nantahala Capital Management, LLC 10% 0% $14,394,468 +$2,168,145 4,112,705 +18% Nantahala Capital Management, LLC 31 Dec 2025
ROYCE & ASSOCIATES LP 7.8% +31% $14,700,547 +$3,731,320 3,274,064 +34% ROYCE & ASSOCIATES LP 30 Jun 2026
Philotimo Fund, LP 5.4% $5,587,269 2,280,518 Kanen Wealth Management LLC 21 Oct 2026
As of 30 Jun 2026, 67 institutional investors reported holding
21.3MFull value: 21,301,578 · shares · 30 Jun 2026
shares of Apyx Medical Corp - Common Stock, $0.001 par value per share (APYX). This represents 50% of the company’s total
42.23MFull value: 42,231,815 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
47%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
ROYCE & ASSOCIATES LP 7.8% 3,274,064 +25% 0.12% $14,700,547
Nantahala Capital Management, LLC 7.7% 3,270,248 -4.9% 0.89% $14,683,414
Archon Capital Management LLC 6.3% 2,644,717 -5.2% 4.8% $11,874,779
VANGUARD CAPITAL MANAGEMENT LLC 3.6% 1,534,847 -1.3% 0% $6,891,463
ESSEX INVESTMENT MANAGEMENT CO LLC 2.7% 1,136,630 +26% 0.67% $5,103,469
AIGH Capital Management LLC 2.7% 1,128,343 +2.1% 0.46% $5,066,260
Silverberg Bernstein Capital Management LLC 2.5% 1,039,641 -0.14% 1.8% $4,667,988
COMMONWEALTH EQUITY SERVICES, LLC 1.5% 649,061 0% 0% $2,914,280
HORIZON KINETICS ASSET MANAGEMENT LLC 1.4% 585,000 -4.9% 0.03% $2,626,650
BlackRock, Inc. 1.3% 560,986 +6.3% 0% $2,518,828
RENAISSANCE TECHNOLOGIES LLC 1.3% 554,278 +83% 0% $2,488,708
Taylor Frigon Capital Management LLC 0.98% 413,602 -0.23% 0.87% $1,857,073
GEODE CAPITAL MANAGEMENT, LLC 0.95% 400,600 +2.4% 0% $1,799,895
Legato Capital Management LLC 0.91% 382,762 +36% 0.14% $1,718,601
SEI INVESTMENTS CO 0.67% 281,029 -53% 0% $1,261,820
Huntleigh Advisors, Inc. 0.62% 263,231 +7% 0.17% $1,181,906
MILLENNIUM MANAGEMENT LLC 0.57% 242,663 -7.4% 0% $1,089,557
MARSHALL WACE, LLP 0.56% 236,466 +282% 0% $1,061,732
VANGUARD FIDUCIARY TRUST CO 0.53% 224,021 +11% 0% $1,005,854
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.51% 216,263 -19% 0% $971,021
Kingsview Wealth Management, LLC 0.51% 214,288 +2.6% 0.01% $962,153
Caption Management, LLC 0.43% 183,003 -1.5% 0.03% $821,683
Hillsdale Investment Management Inc. 0.43% 182,600 +4.8% 0.02% $819,874
Informed Momentum Co LLC 0.4% 170,470 -31% 0.07% $765,410
CITADEL ADVISORS LLC 0.4% 168,344 +56% 0% $755,864

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
32
Headline period
Q2 2026
Rows shown
1-25 of 32
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 2,520,691 $6,175,694 -$273,131 $2.45 5
2026 Q2 21,301,578 $95,637,666 +$2,357,661 $4.49 67
2026 Q1 20,809,791 $76,784,547 +$5,515,763 $3.69 67
2025 Q4 19,119,856 $66,915,648 +$11,936,562 $3.50 59
2025 Q3 15,737,051 $33,674,427 -$213,867 $2.14 47
2025 Q2 15,811,115 $35,574,319 +$288,225 $2.25 39
2025 Q1 15,792,917 $21,635,134 -$202,681 $1.37 43
2024 Q4 15,925,107 $25,160,336 +$4,988,209 $1.58 45
2024 Q3 12,800,031 $15,871,504 -$371,477 $1.24 45
2024 Q2 13,089,462 $17,538,939 -$313,631 $1.34 49
2024 Q1 13,334,937 $18,134,845 -$10,597,896 $1.36 51
2023 Q4 17,452,702 $45,730,029 -$5,190,379 $2.62 62
2023 Q3 18,328,200 $58,651,537 -$229,028 $3.20 61
2023 Q2 18,770,221 $94,412,555 -$2,505,631 $5.03 55
2023 Q1 20,085,109 $58,156,535 +$5,918,433 $2.88 54
2022 Q4 18,191,340 $42,568,844 -$7,872,047 $2.34 48
2022 Q3 20,926,665 $93,963,141 -$1,016,635 $4.49 53
2022 Q2 21,031,854 $123,244,150 +$8,066,381 $5.86 61
2022 Q1 19,582,685 $127,931,812 -$1,520,009 $6.53 70
2021 Q4 19,106,864 $244,910,256 -$2,633,464 $12.82 74
2021 Q3 18,881,855 $261,278,213 +$1,837,936 $13.85 74
2021 Q2 19,074,530 $196,570,403 +$519,685 $10.31 73
2021 Q1 18,975,246 $183,295,913 +$4,233,889 $9.66 67
2020 Q4 18,563,287 $133,715,214 +$4,919,670 $7.20 63
2020 Q3 17,818,092 $83,924,627 -$799,192 $4.71 59
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .